<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation is widely accepted as the first line therapy for patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with less severe forms of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> are treated with <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi>, hematopoietic growth factors or androgenic steroids </plain></SENT>
<SENT sid="2" pm="."><plain>The use of rabbit anti-human thymocyte globulin allowed us to successfully transplant in a patient with a moderately severe form who once failed to respond to <z:hpo ids='HP_0000001'>all</z:hpo> conservative treatment including equine anti-human lymphocyte globulin </plain></SENT>
<SENT sid="3" pm="."><plain>We propose that, given the availability of rabbit anti-human thymocyte globulin, marrow transplantation should be considered in non-severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients who are refractory to equine anti-human lymphocyte globulin </plain></SENT>
</text></document>